Veritas Pharma Retains RWE Growth Partners

July 11, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of RwE Growth Partners, Inc. to evaluate the Company’s $1.50 million investment...

Veritas Pharma Proceeds Towards Clinical Trials

July 10, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd. (CTL) will be sending a team overseas next week...

ACMPR Health Canada Improvements

June 6, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), as an ACMPR applicant would like to notify its investors that Health Canada is introducing several improvements that aim to streamline the ACMPR licensing process....

Cannevert Presses On To Its Goal Of Clinical Trials

May 8, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd. is moving swiftly towards properly certified and...

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!